Spiber Opens Biofoundry to Offer Contract Fermentation and Strain Engineering
Japanese biotech Spiber has launched Spiber Biofoundry, a contract service offering strain engineering and fermentation manufacturing to other companies developing proteins.
The service draws on the company's experience scaling its Brewed Protein materials, with fermenters ranging from one litre to more than 100,000 litres across sites in Japan and Thailand.
Contract fermentation capacity at pilot and commercial scale is scarce, according to Spiber, so access to proven capacity could shorten the route to market for protein and ingredient start-ups.
From Fashion Fibres to a Fermentation Platform
Spiber was founded by Kazuhide Sekiyama, Hideya Mizutani and Junichi Sugahara, and is nearly two decades old. It has raised $489m in funding. Its Brewed Protein is made by feeding microbes on agricultural waste; the resulting protein can be spun into fibres intended to replace materials such as cashmere, leather, wool and silk, as well as plastic-based synthetic fabrics. Spiber says the material is used by more than 40 fashion, personal care and automotive brands across over 200 products.
The company argues that its most valuable asset is not any single material but the platform behind it: strain engineering, fermentation and purification, and a commercial production plan. Spiber also says it was the first company to produce a structural protein material at commercial scale, having built the whole chain in-house, and that its strains now reach titres of 50 grams per litre in its commercial facilities. (A titre is the concentration of product in the fermentation broth, a standard measure of how productive a process is.)
What Spiber Biofoundry Offers
The service has two main parts. In strain development, Spiber optimises the gene sequence for a customer's target protein, introduces it into its proprietary microbial host strains, and evaluates how well it is expressed in culture. In process development and manufacturing, it runs fermentation and purification at scales from one-litre bench fermenters to 2,000-litre vessels at its R&D site in Tsuruoka, Japan, and in commercial fermenters of more than 100,000 litres at its plant in Rayong, Thailand.
Each stage can be commissioned separately, from a single lab-scale evaluation to full production runs. Target product categories include research reagents, industrial enzymes, diagnostic raw materials and food ingredients. Chief executive Maya Kawana said the aim is to help other companies reach market faster, noting that quicker commercialisation eases the burden of ongoing costs.
The Yield Claims
Spiber supports the strain engineering offer with case studies. For each protein, it designed five sequences and tested them against a control. For human FGF-2, a growth factor protein, the company reports yields 5.9 to 9.4 times those of a commercially optimised version. For human interferon-gamma, the improvement was 1.1 to 2.6 times. In broader tests, Spiber-optimised sequences outperformed the benchmark in 90% of the proteins analysed, with yields improving fourfold on average and the best case reaching 40 times.
These figures are the company's own and, as reported, have not been independently verified. The case studies also cover recombinant proteins of the kind used in research and diagnostics, and the report does not say how the results would translate to food ingredients or industrial enzymes.
Why Capacity Matters
The biofoundry targets three problems that Spiber describes as familiar to fermentation companies: yields that stop improving, projects that stall at scale-up, and a shortage of contract manufacturers able to take genetically modified microbes from the lab to commercial volumes. Spiber notes that pilot- and commercial-scale contract capacity is scarce globally, and that few providers have taken a recombinant protein of their own from lab yields to routine commercial production.
That scarcity is a recurring theme in the sector. Other companies have also built their pitch around the scale-up gap, as in Evologic's biotech manufacturing model, and others are extending their reach into Asian markets, such as Norwegian Mycelium with its Japanese subsidiary. Spiber's move adds a materials company with its own production history to the pool of potential partners.
The announcement also fits a wider strategy. Spiber says the biofoundry complements its existing materials business and that its work with strategic partners already extends beyond apparel textiles. Kawana said the service may create new opportunities for collaboration across industries.
Environmental Claims and Open Questions
Spiber's environmental case for Brewed Protein rests on company figures: its fibres generate up to 75% fewer greenhouse gases, use 94% less water and 86% less land than cashmere. These relate to the fibre, not to the contract service, and the report does not describe how they were calculated.
Several questions remain open. The report does not name any customers for the biofoundry, give pricing, or describe how intellectual property would be handled between Spiber and clients. Whether Spiber's host strains and processes perform as well for proteins unlike its own structural proteins will only become clear as customers commission work. The yield improvements, while sizeable in the company's tests, vary widely between proteins, from modest gains for interferon-gamma to a 40-fold peak in the broader set.
For now, Spiber Biofoundry is best read as a bet that proven scale-up experience is a product in itself. Its success will depend on how many outside companies take it up, and on whether the results seen in Spiber's case studies repeat in clients' own projects.
